Antineoplastons Natural Cancer Cure from Your Body

The existence of antineoplastons has been known for decades, though they went unnamed and unexamined. They are peptides (complex molecules built from amino acids) found in blood that most biologists had previously regarded as simply waste products.
It wasn’t until Dr Stanislaw Burzynski discovered that people with cancer had very low levels of these peptides that he began investigating and eventually concluded: “The body itself has a treatment for cancer.”

A neoplasm is another name for a cancer; neo meaning new and plasm meaning formation. Dr Burzynski named the peptides antineoplastons (antineoplasms or anticancers).

When Dr Burzynski began his investigations, early testing showed great promise. He presented his first paper on antineoplastons at the Annual Meeting of Federation of American Societies for Experimental Biology in 1976.

Then the NCI and Mayo Clinic got a hold of them, ran some tests, and gave antineoplastons the thumbs down.

We’ve seen this before (see also, Hydrazine Sulfate).

Antineoplastons, as described by Dr Burzynski, are an integral part of cellular communication. If we see cancer as a miscommunication that leads to rapid, out-of-control growth, then introducing antineoplastons to the equation allows cells to self-correct the problem; this new information (supplied by the antineoplaston) reprograms the cells’ growth pattern, thus healing the cancer.

Another way to look at how antineoplastons work involves gene expression: the process by which the coded information in a gene is converted first into RNA and then into a protein. Antineoplastons attack cancers at the genetic level by expressing the "correct" information that turns off oncogenes (cancer genes) and turning on tumor suppressor genes. Turning off and on specific genes can have a profound effect on how we age, treat, and prevent disease.

In a study carried out by the Department of Defense (in Bethesda, Maryland) antineoplastons in tissue cultures caused cancer cells to revert to normal cells in just two to three days.

Antineoplastons occur naturally in healthy human beings. In cancer patients they are much scarcer. For his research the good doctor originally harvested them from blood, and when his supply of blood ran out, he used urine. Today, he manufactures (synthesizes) them in the laboratory. Dr Burzynski told me that soon, it should be possible to help diagnose cancer by measuring the levels of antineoplastons in simple blood tests.

Antineoplastons must be administered continually to work. Cancer cells must be allowed to revert back to normal cells, and live out their lives to normal cellular death. If the therapy is stopped, the normal cell will once again behave like a cancer cell and take on a remarkable immortal quality—only the patient dies, not the cancer cells.

“There are two ways of administrating antineoplastons.  The first is tablet, or capsule form.  The prescription drug called Buphenyl has been approved by the FDA.  It does not contain antineoplastons; it is converted to antineoplaston AS2-1 in the liver.  It has, so far, no contraindications except extremely rare cases of acute hyperammonemia (a condition in which the blood ammonia levels become elevated).

Daily IV is the usual method of administrating antineoplastons for particularly difficult cancers; an automatic delivery system (miniature pump) provides antineoplastons 6 times a day, though for others whose cancer is not that difficult, they can be treated also on an outpatient basis receiving an IV drip during the night while sleeping.

It should be noted that the prescription drug, Buphenyl, is typically used for less aggressive and less advanced forms of cancer.  It is available only in tablets and that is why the dosage is much smaller than intravenous antineoplastons.  It can be used in any cancer listed for antineoplastons, but in more advanced and more aggressive varieties it is preferred to use Buphenyl in combination with other anticancer agents, such as targeted therapy, immunotherapy, or medium and low doses of chemotherapy.

Dr Burzynski’s clinic in Houston has just completed Phase II trials. They now know which cancers antineoplastons are most effective against.

• Primary brain tumors in children and adults, including glioblastoma, anaplastic astrocytoma, high-grade glioma, brain stem glioma, medulloblastoma, pineoblastoma, oligodendroglioma, mixed glioma, atypical teratoid/rhabdoid tumors, low-grade astrocytoma and visual pathway glioma.
• Colon cancer with liver metastases.
• Primary liver cancer.
• Non-Hodgkin’s lymphoma.
• Prostate cancer.
• Lung cancer.
• Malignant melanoma.
• Pancreatic cancer.
• Esophageal cancer.
• Urinary bladder cancer.
• Multiple myeloma.
• Mesothelioma.
• Adrenal gland cancer.

Improvement is generally seen quite quickly, many patients returning to work after just 6 weeks but still continuing therapy.

Antineoplastons do not seem to interfere with additional conventional or unconventional therapies. They are a part of a healthy human body. When asked if a patient should use diet, nutrition, or possibly alternative therapies along with antineoplastons, Dr Burzynski wrote to me: “Antineoplastons can be used in conjunction with other therapies, both standard and alternative; however, in the United States, we are limited as to what we can use by FDA regulations covering phase II clinical trials.  

In June 2005  we have only one phase II trial protocol in which the patients are treated with a combination of antineoplastons and low-dose chemotherapy.  Japanese doctors have a much wider experience in this respect and they published a number of articles in medical journals about using antineoplastons with various chemotherapeutic agents.”

If you want to use antineoplastons, you either have to attend the Burzynski Clinic, see one of U.S. doctors who are co-investigators, or leave the country. If you contact the clinic, they can tell you where, outside the US, antineoplastons are being used.

Antineoplastons are considered a nontoxic cancer therapy; side effects are minimal, with a very small percentage of patients reporting mild reactions such as gas, skin rashes, blood pressure changes, changes in potassium and sodium concentration in blood, chills, or slight fever. The biggest side effect noticed by most is that they spend a lot more time in the bathroom urinating; due to the amount of liquids they’re receiving intravenously.

It should be noted that in cancer trials around the world, that not only are they finding antineoplastons successful in battling cancer, but that all the researcher seem to think that antineoplastons are a great preventive. Dr Burzynski not only agrees, but has created a monthly supplement to prevent cancer. You can read about it here: Aminocare® A10.

If you would like to try antineoplastons, contact the clinic at www.cancermed.com. While trials continue, the cost of the therapy is much cheaper.

You can read about Dr Burzynski and his struggle to test antineoplastons and help people with cancer by clicking here: Dr Burzynski. Once you’ve read about his trials and tribulations, you’ll be happy to note that in April 2005, the Burzynski Clinic received a note from the FDA stating that the FDA was considering approving antineoplastons for certain cancers.

Description/ Source/ Components
"Burzynski isolated about 120 peptide fragments, amino acid derivatives, and organic acids and termed them antineoplastons, suggesting that the activity of these compounds represents a biochemical adjunct to the immune system. He focused on 2 formulations, which were reproduced synthetically, as being the most active in tumor inhibition-antineoplaston A10 and antineoplaston AS2-1."

"The term 'antineoplastons' is used to describe mixtures of peptides, amino acid derivatives, and organic acids that serve as components of a theoretical natural defense system against human cancers and other human diseases. A10 (a 1:4 ratio of phenylacetylisoglutamine and phenylacetylglutamine [PAG]) and AS2-1 (a 1:4 ratio of PAG and phenylacetic acid) are two such antineoplastons used by Burzynski and associates in the treatment of patients with recurrent anaplastic astrocytoma or glioblastoma multiforme."

Antineoplastons are a group of synthetic compounds that were originally isolated from human blood and urine by Stanislaw Burzynski, M.D., Ph.D., in Houston, Texas. (Cancer Facts 2002)

"Antineoplastons are derived from glutamine, isoglutamine, and phenylacetate salts; antineoplaston AS5 is phenylacetate itself." (Burzynski 1995)

It is administered by injection or orally.